International Journal of Cancer Management

Published by: Kowsar

Metformin Versus Sulfonylurea in Breast Cancer Risk of Diabetic Patients: A Systematic Review and Meta-Analysis

Mohammad Moradi-Joo 1 , Sahar Mohabbat-Bahar 2 , Saeed Heidari 3 , Sayed Hossein Davoodi 4 , Sepideh Gareh Sheyklo 5 and Mohammad-Esmaeil Akbari 1 , *
Authors Information
1 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Faculty of Psychology and Educational Sciences, Ferdowsi University of Mashhad, Khorasan Razavi, IR Iran
3 Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, IR Iran
4 Department of Clinical Nutrition and Dietology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences, Food Science and Technology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
5 Dezful University of Medical Sciences, Dezful, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: October 2016, 9 (5); e5971
  • Published Online: September 19, 2016
  • Article Type: Review Article
  • Received: March 10, 2016
  • Revised: June 8, 2016
  • Accepted: September 10, 2016
  • DOI: 10.17795/ijcp-5971

To Cite: Moradi-Joo M, Mohabbat-Bahar S, Heidari S, Davoodi S H, Gareh Sheyklo S, et al. Metformin Versus Sulfonylurea in Breast Cancer Risk of Diabetic Patients: A Systematic Review and Meta-Analysis, Int J Cancer Manag. 2016 ; 9(5):e5971. doi: 10.17795/ijcp-5971.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90[DOI][PubMed]
  • 2. Akbari M, Khayamzadeh M, Khoshnevis SJ, Nafisi N, Akbari A. Five and ten years survival in breast cancer patients mastectomies vs. breast conserving surgeries personal experience. Iranian J Cancer Prevent. 2012; 1(2): 53-6
  • 3. Cancer registration country reports 2009 2012;
  • 4. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007; 86(3): 823S-5S
  • 5. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008; 109(2): 389-95[DOI][PubMed]
  • 6. De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013; 100(11): 1421-9[DOI][PubMed]
  • 7. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013; 37(3): 207-18[DOI][PubMed]
  • 8. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011; 9: 33[DOI][PubMed]
  • 9. Schafer G. A review of history, pharmacodynamics and therapy. Diabete Metabolism. 1982; 9(2): 148-63
  • 10. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010; 9(5): 1092-9[DOI][PubMed]
  • 11. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33(6): 1304-8[DOI][PubMed]
  • 12. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 2009; 18(3): 701-5[DOI][PubMed]
  • 13. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012; 135(3): 639-46[DOI][PubMed]
  • 14. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3(11): 1451-61[DOI][PubMed]
  • 15. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2): 254-8[PubMed]
  • 16. DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat. 2014; 148(1): 81-90[DOI][PubMed]
  • 17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11): 1539-58[DOI][PubMed]
  • 18. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373(9681): 2125-35[DOI][PubMed]
  • 19. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35(2): 299-304[DOI][PubMed]
  • 20. Hsieh M, Lee T, Cheng S, Tu S, Yen M, Tseng C. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Experimental Diabet Res. 2012; 2012
  • 21. Redaniel MT, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control. 2012; 23(11): 1785-95[DOI][PubMed]
  • 22. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia. 2012; 55(3): 654-65[DOI][PubMed]
  • 23. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012; 35(1): 119-24[DOI][PubMed]
  • 24. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013; 15(4): 349-57[DOI][PubMed]
  • 25. Soffer D, Shi J, Chung J, Schottinger JE, Wallner LP, Chlebowski RT, et al. Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care. 2015; 3(1): 49[DOI][PubMed]
  • 26. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014; 37(9): 2522-32[DOI][PubMed]
  • 27. Chen YC, Kok VC, Chien CH, Horng JT, Tsai JJ. Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator. Ther Clin Risk Manag. 2015; 11: 1315-23[DOI][PubMed]
  • 28. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012; 17(6): 813-22[DOI][PubMed]
  • 29. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013; 8(8): 71583[DOI][PubMed]
  • 30. 13 . Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012; 135(3): 639-46[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments